Efficacy and safety of ABP 798 compared with rituximab: Results from the comparative clinical study in patients with non-Hodgkin’s.
Predictors of accrual success for cooperative group trials: The Cancer and Leukemia Group B (Alliance) experience. Background: Management of advanced malignancies in SOT recipients is not well defined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results